Other News To Note
Nektar Therapeutics Inc., of San Francisco, said preclinical data were reported at the Society for Neuroscience meeting in New Orleans for NKTR-171, a sodium channel blocker to treat neuropathic pain.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST